The phase II HERIZON trial was randomized to either HER-Vaxx plus standard chemotherapy or standard chemotherapy alone in patients with HER2/neu overexpressing metastasizing or advanced gastric/GEJ adenocarcinoma who were naïve to HER2 therapy [138]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.